NewsDialy
A clinical trial set to begin next week in the Democratic Republic of the Congo will test Gilead Sciences' antiviral drug remdesivir and MappBio's monoclonal antibody MBP-134 against the Bundibugyo ebolavirus, the World Health Organization announced Wednesday.
The trial, prompted by a fast-moving outbreak in Central Africa, will assess each drug separately and examine whether combining them produces stronger results.
What Is Bundibugyo Ebolavirus — and Why the Species Label Matters Ebola is not a single disease but a family of related viruses, and the specific species driving an outbreak determines which treatments are likely to work.
Bundibugyo ebolavirus is a distinct member of that family.
Keep reading